Project Grant R00AT012494
Award Date 8/10/26
Completion Date 7/31/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Orange, CA 92868, USA
Similar Awards
- The National Center for Complementary and Integrative Health (NCCIH), part of the U.S. Department of Health and Human Services, awarded a $437,458 Project Grant under CFDA Program 93.213 "Research and Training in Complementary and Integrative Health" to the University of Illinois. The grant will fund a 2-year randomized crossover study exploring the effects of a Mediterranean diet on gut microbiome composition and chronic pain in 24 adults with sickle cell disease. The study aims to...
- The National Institute of Neurological Disorders and Stroke awarded Duke University $3.119 million on September 18, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate computational and clinical tools for understanding pain variability in sickle cell disease. The funded work constitutes a prospective cohort study enrolling 1,250 individuals aged 15 years and older living with sickle cell disease in the United States. Over three years, the research...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $834,899 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify inflammatory biosignatures that distinguish pain phenotypes in sickle cell disease. The research, titled "Inflammatory Biosignatures for the Identification of Sickle Cell Associated Pain Phenotypes (IBIS-CAP)," develops proteomic signatures composed of multiple biomarkers to characterize...
- The National Institute of Neurological Disorders and Stroke awarded the University of Texas at Arlington $2,083,992 on September 18, 2025, to conduct longitudinal collection and computational modeling of health data in Black adolescents and young adults with sickle cell disease, with an ultimate completion date of August 31, 2030. The project, titled "Modeling Inter-Individual Differences to Address Pain of Sickle Cell Disease (MIDAS)," is supported under the Drug Use and Addiction...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $746,979 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of pain in sickle cell disease. The research uses transgenic mice with sickle cell disease to study how vaso-occlusive crises trigger severe pain. The project examines the role of lysophosphatidic acid (LPA), a pain mediator elevated during hypoxia-induced vaso-occlusion, and tests...
- The National Heart, Lung, and Blood Institute awarded the University of Texas at Dallas $641,538 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL181083) to investigate gut microbiome targets for sickle cell disease pain management. The research addresses chronic pain in individuals with sickle cell disease, a leading complication that persists despite advances in disease-modifying and curative therapies and is often managed with...
- The National Heart, Lung, and Blood Institute awarded Yale University $841,906 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, to conduct the SPIRIT-2 Study examining high-impact chronic pain in sickle cell disease. The study addresses three critical gaps in sickle cell disease pain management: identifying risk factors for sustained high-impact chronic pain and poor long-term outcomes; developing patient-centered endpoints to assess intervention efficacy from...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $168,351 on September 1, 2026, to develop and pilot-test a stigma reduction intervention targeting pain management in adults with sickle cell disease under the Cardiovascular Diseases Research program (CFDA 93.837). Dr. Lakeya McGill's K23 mentored career development award funds research, mentorship, and training to support her transition to independent investigator status. The project develops a patient-facing...
- Midwestern University received a $1.76M Project Grant from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning August 1, 2025, and extending through July 31, 2029. The award supports research to develop microRNA (miRNA) as a novel therapeutic target for pain management in sickle cell disease (SCD). The project focuses on investigating let-7 family microRNA as a potential intervention to alleviate chronic pain in...
- The National Center for Complementary and Integrative Health of the Department of Health and Human Services awarded Southern California University of Health Sciences $535,524 on August 15, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to assess the quality and value of non-pharmacological therapies compared to prescription drug therapy for managing spinal pain in Medicare beneficiaries aged 65 and older. The research will use Medicare...